Hemab Therapeutics Shares Jump After Multi-Program Data Package and New Pipeline Addition
Hemab Therapeutics shares climbed roughly 13.0% in mid-day trading after the company disclosed nine presentations spanning three programs ahead of the International Society on Thrombosis and Haemostasis 2026 Congress in Paris. The update included first-in-human proof-of-mechanism data for HMB-002 in Von Willebrand disease, long-term extension findi…